Characterization of two polymorphs of lornoxicam

Zhang, Jianjun; Tan, Xin; Gao, Jing; Fan, Weiming; Gao, Yuan; Qian, Shuai

doi:10.1111/j.2042-7158.2012.01573.x

Cited by 17 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(6-Chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2thiazine-3-carboxamide 1,1-dioxide, C13H10ClN3O4S2, Fig.1) is a non-steroidal antiinflammatory drug (NSAID) that belongs to the "oxicam" class, which presents analgesic, anti-inflammatory and antipyretic properties [1,2,3]. It is used in musculoskeletal and joint disorders such as osteoarthritis and rheumatoid arthritis.…”

Section: Lornoxicammentioning

confidence: 99%

Lornoxicam drug—A new study of thermal degradation under oxidative and pyrolysis conditions using the thermoanalytical techniques, DRX and LC-MS/MS

et al. 2019

View full text Add to dashboard Cite

In the present work, the thermal behavior of Lornoxicam drug was studied under oxidizing (air) and pyrolysis (N2) atmospheres using simultaneous thermogravimetry and differential scanning calorimetry (TG-DSC), differential scanning calorimetry (DSC), Hot Stage Microscopy (HSM) and Evolved Gas Analysis (EGA) in the form of thermogravimetry coupled to infrared spectroscopy (TG-FTIR) and mass spectrometry (TG-MS). The thermal degradation product formed at different temperatures were examined using liquid chromatography coupled to mass spectrometry (LC-MS) and Powder X-Ray Diffraction (PXRD). The thermal study showed that the drug does not melt, partially amorphized on heating, it is thermally stable to 205 °C and undergoes thermal decomposition in two overlapping mass loss steps. Furthermore, the DSC and MS techniques suggest that thermal degradation processes are very complex, which occur with the release of gaseous products HCN, SO2, COS, CO2, N2O and CO and formation of three intermediate in the thermal residue.

show abstract

Section: Lornoxicammentioning

confidence: 99%

Lornoxicam drug—A new study of thermal degradation under oxidative and pyrolysis conditions using the thermoanalytical techniques, DRX and LC-MS/MS

et al. 2019

View full text Add to dashboard Cite

show abstract

“…3 . Lornoxicam exits in two polymorphic forms ( Zhang et al, 2013 ). XRD patterns resembled that of polymorph form II with sharp peaks appearing at 22.03°, 23.82°, 26.06°, 30.35° and 33.49° at the 2-theta scale, corresponding to crystalline nature of lornoxicam.…”

Section: Resultsmentioning

confidence: 99%

Formulation and characterization of lornoxicam-loaded cellulosic-microsponge gel for possible applications in arthritis

He¹,

Majid

Maqbool

et al. 2020

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease associated with severe joint pain. Herein, we report lornoxicam loaded cellulosic microsponge gel formulation with sustained anti-inflammatory effects that are required to manage arthritic pain. The microsponges were formulated using quasi emulsion-solvent diffusion method employing four different surfactant systems, namely polyvinyl alcohol (PVA), Tween80, Gelucire 48/16 and Gelucire 50/13. All the lornoxicam loaded microsponge formulations were extensively characterized with a variety of analytical tools. The optimized microsponge formulation was then converted into gel formulation. The lornoxicam loaded microsponge gel formulation had adequate viscosity and sufficient pharmaceutical properties as confirmed by the texture analysis and the drug release followed Super case II transport. It is noteworthy that we described the preparation of a new cellulosic polymers based microsponge system for delivery of lornoxicam to provide quick as well as lasting (sustained) anti-inflammatory effects in rats using carrageenan induced rat paw edema model. We were able to demonstrate a 72% reduction in inflammation within 4 h using the optimize transdermal gel formulation utilizing Transcutol P as permeation enhancer and with the aid of skin micro-piercing by microneedles, hence, demonstrating the potential of this microsponge gel formulation in arthritis management.

show abstract

“…The solubility of lornoxicam showed strong pH dependence, as the solubility increased along with the pH step up. [18] The stability of lornoxicam for injection in 0.9% sodium chloride injection prepared according to clinical regime showed that no significant change in 72 hours. [19] However, drug incompatibility was occurred when lornoxicam combined with butorphanol tartrate or fentanyl citrate injection in 0.9% sodium chloride injection for PCA used.…”

Section: Discussionmentioning

confidence: 99%

Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration

Fang

Shi²,

Chen³

et al. 2016

Medicine

View full text Add to dashboard Cite

The administration of drugs by patient-controlled analgesia (PCA) is routinely practiced for the management of postoperative pain. It is common for 2 or more drugs to be combined in PCA solutions. The combination of analgesics and antiemetic agents is frequently required. Unfortunately, the compatibility and stability of lornoxicam and antiemetic agents, such as droperidol, ondansetrone, granisetron, and tropisetron, has not been determined. The aim of this study was to evaluate the compatibility and stability of solutions containing lornoxicam with the 4 antiemetic agents in combination for PCA administration.In our study, test samples were prepared in triplicate by adding 40 mg lornoxicam and 5 mg droperidol, 8 mg ondansetron, 6 mg granisetron, or 5 mg tropisetron to 100-mL polyolefin bags of sodium chloride 0.9% and stored at 25 °C. The analgesic mixture samples were visually inspected for precipitation, cloudiness, and discoloration at each sampling interval. Drug concentrations were determined using high-performance liquid chromatographic (HPLC) analysis.No loss of lornoxicam occurred with any of the 4 antiemetic agents tested for up to 48 hours. However, the contents of droperidol, ondansetron, granisetron, and tropisetron were significant loss >48 hours. After storage of 4.0 to 48.0 hours, the presence of a slight precipitate was observed in all the injection combinations.The results indicate that combinations of lornoxicam with droperidol, ondansetrone, granisetron, or tropisetron in infusion solution during simulated intravenous PCA administration were incompatibility when stored protected from light at 25 °C.

show abstract

Characterization of two polymorphs of lornoxicam

Abstract: Form II had the significantly higher solubility and dissolution and would be the suitable polymorph for the preparation of oral and injectable dosage forms of lornoxicam.

Cited by 17 publications

References 37 publications

Lornoxicam drug—A new study of thermal degradation under oxidative and pyrolysis conditions using the thermoanalytical techniques, DRX and LC-MS/MS

Lornoxicam drug—A new study of thermal degradation under oxidative and pyrolysis conditions using the thermoanalytical techniques, DRX and LC-MS/MS

Formulation and characterization of lornoxicam-loaded cellulosic-microsponge gel for possible applications in arthritis

Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration

Contact Info

Product

Resources

About